According to a post on the FDA’s website, Candel Therapeutics’ treatment of pancreatic cancer received orphan designation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics Inc trading resumes
- Candel Therapeutics Inc trading halted, volatility trading pause
- Candel Therapeutics Shows Promising Pancreatic Cancer Trial Results
- Candel Therapeutics announces interim data from Phase 2 trial of CAN-2409
- Candel Therapeutics presents updated data from Phase 1b trial of CAN-3110
